Short answer
OptimizeRx Corp (OPRX) filed its Q3 2026 10-Q quarterly report on Nov 13, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $22M (down 17.1% year over year) with net income of $1M.
Q3 2026 key financials · XBRL
- Revenue
- $22M
- −17.1% YoY · +5.4% QoQ
- Net income
- $1M
- +53.4% YoY · +270.0% QoQ
- Operating margin
- 12.4%
- EPS (diluted)
- $0.06
- +20.0% YoY · +300.0% QoQ
Source: XBRL data from the OptimizeRx Corp (OPRX) Q3 2026 10-Q on SEC EDGAR. USD.
OptimizeRx Corp Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $21,615, down 17% YoY from $26,067, reflecting managed-service declines and measured customer spending
- Operating margin 12.4% vs 7.9% YoY, with net income $1,195 vs $779
- Cost of revenue margin 25% vs 33%, driven by exiting low-margin managed services
- Operating cash flow $12,880 vs $11,627; cash $22,325 and undrawn revolver $10,000
- Outlook: sufficient liquidity for 12 months, with headwinds from tariffs, macroeconomic uncertainty and customer budget scrutiny
Risk Factors
- No material changes from the December 31, 2025 Form 10-K risk factors
- Carried-forward business risks could materially affect operations and financial condition
- Additional unidentified or currently immaterial risks could adversely affect operating results
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other OptimizeRx Corp quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.